目的 探讨CHB患者自然史不同阶段的血清外泌体中差异表达的miRNA及其临床意义.方法 2014年1月至2017年1月上海市(复旦大学附属)公共卫生临床中心C HB初治患者92例,其中免疫耐受期24例,免疫清除期24例,低复制期24例,再活动期20例.采用ExoQuick试剂盒抽提250μL血清中的外泌体,通过蛋白免疫印迹法检测外泌体蛋白标志物LAMP2和TSG101的表达;实时荧光定量PCR技术检测miRNA-122、miRNA-125a、miRNA-29c、miRNA-200c在血清外泌体中的表达.组间差异比较采用Mann-Whitney U检验和Kruskal-Wallis H检验;关联性分析采用皮尔逊相关系数;用受试者工作特征曲线(receiver operating characteristic,ROC曲线)来评估预测效能.结果 蛋白质免疫印迹法检测外泌体表面特异性标志物LAMP2和TSG101阳性.CHB患者血清外泌体中的miRNA-122(H=41.06)、miRNA-125a(H=29.31)、miRNA-29c(H=49.14)和miRNA-200c(H=31.73)在自然史不同阶段表达差异均有统计学意义(均P<0.01).根据肝功能指标及肝穿刺结果,与无炎症组相比,炎症组血清外泌体的miRNA-122(U=804)、miRNA-29c(U=317)和miRNA-200c(U=574)均下调(均P<0.05),而miRNA-125a上调(U=279,P<0.01).miRNA-200c与ALT呈负相关(r=-0.3932,P<0.01),而miRNA-125a与ALT呈正相关(r=0.5981,P<0.01).通过ROC曲线来评价外泌体源miRNA-122、miRNA-125a、miRNA-29c和miRNA-200c对炎症的诊断价值,曲线下面积分别为0.6193、0.8396、0.8243和0.6883,其中miRNA-125a曲线下面积最大,敏感度为84.62％,特异度为74.47％.而ALT区分肝穿刺有无炎性反应的ROC曲线下面积为0.7953,敏感度为81.08％,特异度为70.97％.结论 外泌体源性miRNA在CHB患者自然史不同阶段中的表达存在明显差异,与炎性反应相关的外泌体源miRNA有望成为诊断肝脏炎性反应的新型无创生物学标志物,帮助确定C HB患者临床用药治疗的最佳时机.%Objective To explore the expression profiles and their clinical significance of serum exosomal microRNA (miRNA ) in the different phases of natural history in chronic hepatitis B (CHB ) patients .Methods A total of 92 treatment-naive CHB patients in Shanghai Public Health Clinical Center between January 2014 and January 2017 were retrospectively studied .The cases in immune tolerant (IT) phase ,immune reactive (IR) phase ,inactive carrier (IC) phase and HBeAg-negative CHB (ENH) phase were 24 ,24 ,24 ,and 20 ,respectively .Exosomes were isolated by ExoQuick solution from 250μL serum . The expressions of the surface protein markers LAMP2 and TSG101 in serum exosomes were determined by Western blotting . The expressions of miRNA-122 , miRNA-125a , miRNA-29c , miRNA-200c in exosomes were detected by real-time fluorescent quantitative PCR .The Kruskal-Wallis H test and Mann-Whitney U test were used to determine intergroup differences . The correlation coeffcients ( r) were calculated using Spearman′s correlation .Receiver operating characteristic (ROC) and the area under the curve (AUC ) were used to calculate the diagnostic values . Results Western blotting showed that exosome-specific markers LAMP2 and TSG101 were positive .The levels of serum exosomal miRNA-122 , miRNA-125a ,miRNA-29c and miRNA-220c were significantly different in CHB patients in different phases (H=41 .06 ,29 .31 ,49 .14 and 31 .73 ,respectively ,all P<0 .05) .Based on the results of liver function test and liver biopsy , serum exosomal miRNA-122 , miRNA-29c and miRNA-200c in inflammation group were down-regulated (U = 804 ,317 and 574 ,respectively ,all P< 0 .05) ,while miRNA-125a was up-regulated (U=279 ,P<0 .01) compared with non-inflammation group .The level of exosomal miRNA-200c was negatively correlated with ALT (r= -0 .3932 ,P<0 .01) ,while the level of miRNA-125a was positively correlated with ALT (r=0 .5981 , P<0 .01) .AUC of the above exosomal miRNA were 0 .6193 ,0 .8396 ,0 .8243 and 0 .6883 ,respectively .The highest AUC was miRNA-125a with the sensitivity of 84 .62％ and the specificity of 74 .47％ .AUC of ALT discrimination for liver inflammation was 0 .7953 ,with the sensitivity of 81 .08％ and the specificity of 70 .97％ .Conclusions The serum exosomal miRNA levels are significantly different among the different phases of natural history in CHB patients .Inflammation-associated exosomal miRNA is expected to be the non-invasive diagnostic biomarkers of liver inflammation and is of great benefit for determining the best time for clinical medication of CHB patients .
展开▼
